Can you take semaglutide and tirzepatide at the same time?

You're already on one, and wondering if adding the other would help

This is the scenario our prescribers hear fairly often. Someone has been on Wegovy for a few months, progress has slowed, and they have read that tirzepatide produces greater average weight loss in trials. Or the reverse: a patient on Mounjaro reads that semaglutide has a longer safety record and wonders about combining them. If you are asking whether you can mix semaglutide and Mounjaro, the short answer is the same in both directions: you cannot take semaglutide and tirzepatide at the same time.

Tirzepatide activates two receptors, GIP and GLP-1. Semaglutide activates the GLP-1 receptor alone. Running both together means the GLP-1 pathway is being stimulated by two separate medicines simultaneously. The likely result is compounded gastrointestinal side effects (persistent nausea, vomiting, severe diarrhoea) and an elevated risk of dehydration and related complications, including kidney stress. No clinical trial has studied this combination in humans for weight management, which means there is no safety data to draw on and no licensed indication for it.

If you feel your current treatment has plateaued, the right move is to raise it with your prescriber at your next review. Dose adjustment, a structured break, or a supervised switch to the other medicine are all options a clinician can assess. Our clinical team fields this question regularly and can walk through the options with you.

What the trial evidence says when they are compared head to head

The honest picture is that tirzepatide and semaglutide have not been compared in a head-to-head trial until recently, and even now the comparison comes with caveats worth understanding before drawing conclusions.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide with semaglutide 2.4mg over 72 weeks in adults with obesity and no type 2 diabetes. Participants on tirzepatide lost more weight on average. SURMOUNT-1 had already shown around 20–21% average body-weight reduction at the highest tirzepatide dose; STEP 1 found approximately 15% average loss with semaglutide 2.4mg over 68 weeks. The gap is real, though it narrows at the higher 7.2mg semaglutide dose approved by the MHRA in early 2026.

The table below sets out the key factual differences, not to declare a winner, but to give you a clear starting point for a conversation with a prescriber. For a fuller side-by-side look, our Wegovy vs Mounjaro comparison goes into more depth on mechanism, eligibility and side-effect profiles.

Source: NICE TA1026; NEJM SURMOUNT-1; NEJM STEP 1.

Switching between them: what that process actually looks like

Switching from semaglutide to tirzepatide, or the other way around, is clinically possible, but it is a prescriber-led process, not a self-directed one. There is no standard published washout period in UK guidance for moving between these two medicines, which is precisely why a clinician needs to manage it: they assess your current dose, how long you have been on it, your recent side-effect pattern and your overall health before deciding the right approach.

At a practical level, one thing you can do right now is check the GPhC register to confirm that any pharmacy you are using or considering is properly registered, the search takes under a minute at pharmacyregulation.org/registers. That single check rules out counterfeit supply, which the MHRA has warned about repeatedly in relation to GLP-1 medicines.

If you are currently on treatment elsewhere and want to switch medicines or provider, our consultation process covers transfer patients, you will be asked to provide evidence of your current treatment and dose. Questions about which medicine is right for you, or whether switching makes sense, are exactly what the free consultation is for. Related detail on the mechanics of combining or switching is covered in our guide on taking semaglutide and tirzepatide at the same time and on mixing tirzepatide and semaglutide.

Which medicine is right for you, and how that decision gets made

Neither medicine is universally the better choice. Tirzepatide's trial results show greater average weight loss at the headline level, but individual response varies considerably, and factors like tolerability, existing conditions, other medicines you take and personal preference all feed into the decision. Some people do better on semaglutide; some find the dual mechanism of tirzepatide suits them; the trial averages tell you about populations, not individuals.

The semaglutide or tirzepatide comparison page runs through the clinical factors in more detail, including the oral semaglutide tablet option approved in the UK in June 2026 for people who prefer not to inject. On the cost side, pricing context for both medicines is worth reading before you decide, since the list prices differ meaningfully by dose and have changed since Eli Lilly adjusted Mounjaro's pricing in September 2025.

Both medicines are prescription-only. A prescriber (not a comparison article) makes the final call on suitability. Which suits you is a clinical decision our prescribers make with you, based on your health history, your goals and how your body has responded if you have taken either medicine before. Start your free consultation to begin that conversation.